Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.

Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Alnylam has got the go-ahead for a second – Amvuttra – which has a simpler ...

Cantor Fitzgerald said that while the firm “congratulates” Alnylam Pharmaceuticals (ALNY) on last week’s Amvuttra approval, with the stock approaching $300, Cantor is struggling with ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Food and Drug Administration (FDA) to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a potentially fatal disease of the ...

In one study, Alnylam Pharmaceuticals' Amvuttra helped lower the risk of death and heart problems by 28% over three years compared to a placebo. The drug is given as a shot every three months.

A program called Alnylam Assist may also be available. »Learn more about saving on your prescriptions. If you’d like to explore an alternative to Amvuttra, talk with your doctor. They can ...

The increased compensation for Greenstreet comes after a big 2024 for the Cambridge drugmaker during which Alnylam laid out promising Phase 3 data for the drug Amvuttra in a rare heart disease ...

FDA approved Alnylam's Amvuttra for ATTR-CM, making it the first treatment cleared for both ATTR-CM and hATTR-PN in adults. JP Morgan upgraded Alnylam to Overweight, citing strong Amvuttra sales ...

said in a news release by Alnylam, the maker of Amvuttra. "The availability of this groundbreaking treatment option is a significant moment for patients living with ATTR amyloidosis. It ...

As Alnylam approaches a potential milestone with its lead product Amvuttra, investors and analysts are closely watching its progress in this rapidly expanding market. Want deeper insights into ...

Federal officials have approved Alnylam's new heart drug, Amvuttra The treatment lowered risk of death and heart issues by 28% in one study It costs roughly $476,000 a year MONDAY, March 24 ...

The drug, called Amvuttra (vutrisiran), is made by Alnylam Pharmaceuticals Inc. and is used to treat transthyretin amyloid cardiomyopathy. ATTR-CM is a disease in which harmful proteins build up ...